1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNo fixed deadline; fund opens and closes based on availability — applicants can join a waitlist when closed.
Asthma medications copay assistance grant is sponsored by PAN Foundation. This grant provides copay assistance for asthma medications to help individuals afford out-of-pocket costs for covered prescription medications. As of July 1, 2026, grants will be offered first-come, first-served through the TotalAssist program.
Get alerted about grants like this
Save a search for “PAN Foundation” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Asthma medications copay assistance grant The PAN Foundation and Patient Advocate Foundation announced a strategic merger in March 2026. In the meantime, nothing is changing for patients. You can continue to apply for and use financial assistance from the PAN Foundation through panapply.
org or by calling us at 1-866-316-7263. You can learn more about the announcement at uniting. patientadvocate.
org . ICD-10: J45. 20, J45.
21, J45. 22, J45. 30, J45.
31, J45. 32, J45. 40, J45.
41, J45. 42, J45. 50, J45.
51, J45. 52, J45. 901, J45.
902, J45. 909, J45. 990, J45.
991, J45. 998, J82. 83 Asthma, also known as bronchial asthma, is a respiratory disease characterized by airflow obstruction and inflammation of the airways.
It is a chronic disease that affects the respiratory system. Source: National Institutes of Health If this fund is open , and you are eligible, apply today. If this fund is closed , join the wait list.
If a fund is open to wait list only , people currently on the wait list can apply using the link sent by email.
Before you apply, make sure you have this information ready: Your diagnosis and medications Your provider’s contact information, including name, and phone number Your health insurance carrier name and your insurance member ID Your contact information, including email and social security number Your adjusted gross annual household income Healthcare providers and pharmacies will be asked for additional information.
Read our guide to enrolling your patients . If you don’t already have a healthcare provider PAN portal account, register for one before applying ; registration may take 1 to 2 business days. For faster registration, call us during business hours.
To apply by phone, call us at 1-866-316-7263 Monday through Friday, 9:00 a. m. to 5:30 p.
m. ET. Our representatives will help you with your pre-screening and application over the phone.
Have your information ready. Translators are available if needed. Need help?
Read our step-by-step guides to creating your account and applying, or call us for help at 1-866-316-7263, Monday through Friday, 9:00 a. m. to 5:30 p.
m. ET. If a fund is closed, you can join the wait list in one of two ways: find your fund and join the wait list from our website , or login to your PAN portal account, find your fund, and join the wait list.
If requested by PAN, how to verify your income or insurance: Sometimes, we may conditionally approve your application, and we will request that you verify your income for copay grants, or provide documentation of health insurance premium for insurance premium grants.
Verify your insurance premium Get alerts when funds open at several organizations with FundFinder: Explore patient resources Get clinical trial support Get support services from our featured partner: The American Lung Association provides patient education and engages in advocacy work and research focused on improving lung health and the prevention of lung disease.
Learn more about partners American Lung Association Asthma and Allergy Foundation of America Voice your support for healthcare access and affordability. Make your life-changing donation to support healthcare access.
Based on current listing details, eligibility includes: Individuals receiving treatment for asthma, residing and receiving treatment in the United States or U.S. territories, having government-insured health coverage (Medicare, Medicaid, or TRICARE) that covers their qualifying medication, being prescribed a medication on PAN's covered list, and having an income at or below 400% of the Federal Poverty Level. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates $1,500 initial grant (up to $3,000 per year) Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
Japan Global Network Collaborative Grants is sponsored by Social Science Research Council and The Japan Foundation, New York. These collaborative grants support members of the Abe Fellows Network and the U. S. -Japan Network for the Future program for research, fact-finding, convenings, and public engagement around global issues viewed through a Japanese lens.
Japan Global Network Collaborative Grants is sponsored by Social Science Research Council (SSRC) and The Japan Foundation, New York. These grants support members of the Abe Fellows Network and the U. S. -Japan Network for the Future program for research, fact-finding, convenings, and public engagement on policy-relevant and contemporary global issues using Japan as a lens.
U.S.-Japan Foundation Grant Program is a quarterly grant cycle from the United States-Japan Foundation (USJF), an independent charitable organization that has awarded more than $100 million in grants to strengthen bilateral ties between the United States and Japan. The program funds advocates, artists, scholars, and students working to advance U.S.-Japan relations and confront shared challenges. Grants are decided per project, with no set maximum amount. The 2026 second quarter window is open with a June 26 deadline; the foundation operates four application cycles per year. Eligible applicants include nonprofits, educational institutions, and other entities with demonstrable impact on U.S.-Japan relations.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.